Our results suggest that IGF1R has variable expression – on, or 1, in some tumors and off, or 0, in others – in patients within the same GBM survival class, indicating that experimental IGF1R monotherapies [20], [21], while inappropriate as a population-level intervention, may be highly effective in precisely selected individuals. The gene discussed is IGF1R; the disease is glioblastoma.